Expression of IL-1β, IL-1 Receptor Type I and IL-1 Receptor Antagonist in Human Aortic Smooth Muscle Cells: Effects of all-trans-Retinoic AcidWågsäter D.a · Jatta K.a · Ocaya P.a · Dimberg J.b · Sirsjö A.a
aDivision of Biomedicine, Department of Clinical Medicine, University of Örebro, Örebro, and bDepartment of Natural Science and Biomedicine, University College of Health Sciences, Jönköping, Sweden
The proinflammatory cytokine interleukin (IL)-1β and the IL-1 receptor antagonist are expressed by atherosclerotic plaques and may be linked to the development of atherosclerosis. Existing evidence shows that retinoids and their receptors are involved in inflammatory response and that they are found in atherosclerotic plaques. In all-trans-retinoic acid (atRA)-treated human aortic smooth muscle cells (AOSMC), significant increases in IL-1β levels were observed, compared with untreated cells. Examination of IL-1 receptor antagonist and IL-1 receptor type I levels did not show any difference between atRA-treated and -untreated AOSMC. The results show that atRA-treated AOSMC express both the precursor (33 kDa) and the active form (17 kDa) of the IL-1β protein. atRA-treated carotid lesions showed significantly elevated IL-1β mRNA levels (2.9 ± 2.33) compared with untreated lesions (2.0 ± 1.77; p < 0.05). These results support the role of atRA as a regulator of inflammation such as in atherosclerosis.
© 2006 S. Karger AG, Basel
D.W. and K.J. contributed equally to this article.
Received: October 21, 2005
Accepted after revision: May 3, 2006
Published online: June 28, 2006
Number of Print Pages : 6
Number of Figures : 2, Number of Tables : 0, Number of References : 34
Journal of Vascular Research (Incorporating 'International Journal of Microcirculation')
Vol. 43, No. 4, Year 2006 (Cover Date: July 2006)
Journal Editor: Pohl, U. (Munich)
ISSN: 1018–1172 (print), 1423–0135 (Online)
For additional information: http://www.karger.com/JVR